IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | US

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Haleon PLC A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.	United Kingdom	HLN
Halychpharm A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.	Ukraine	GFARM
HANALL BIOPHARMA CO.,LTD Develops innovative medicines for chronic diseases through antibody and small molecule research.	South Korea	009420
Hana Pharm. Co., Ltd. Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.	South Korea	293480
Hanmi Pharm. Co., Ltd. Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.	South Korea	128940
Hansa Biopharma Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.	Sweden	HNSA
Harmony Biosciences Holdings, Inc. Develops innovative therapies for rare neurological diseases, focusing on conditions like narcolepsy.	United States of America	HRMY
HARROW, INC. Develops branded ophthalmic therapies and custom compounded solutions for North American eyecare.	United States of America	HROW
HCW Biologics Inc. Developing novel immunotherapies to treat aging-related chronic inflammation.	United States of America	HCWB
HEALIOS K.K. Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.	Japan	4593